Please enable JS

About

Collaborations

Collaborations and business development are integral to our growth strategy and have played a key role in our complex generics and biosimilars business.

Complex Generics

Momenta has two major complex generic collaborations with Sandoz, a division of Novartis.

  • In 2003, Momenta entered into a collaboration and license agreement with Sandoz for the development and commercialization of enoxaparin sodium injection in the United States. The resulting product, marketed by Sandoz, was the first generic version of LOVENOX® (enoxaparin sodium injection) to be approved by the FDA.
  • In 2006, Momenta and Sandoz entered into a collaboration and license agreement for the worldwide development and commercialization of a generic form of daily COPAXONE® 20 mg/mL (glatiramer acetate injection). The resulting product, marketed by Sandoz, Glatopa® is the first fully substitutable once daily generic equivalent of daily COPAXONE® 20 mg/mL to be approved by the FDA.  Momenta and Sandoz are currently collaborating on the development and commercialization of M356, a generic version of three times weekly COPAXONE® 40mg/mL (glatiramer acetate injection).

Biosimilars

In January 2016, Momenta entered into a broad global collaboration with Mylan for the development, manufacture and commercialization of six of Momenta’s biosimilar candidates, including M834, Momenta's ORENCIA® (abatacept) biosimilar candidate.

What type of collaborations are we looking for?

Momenta is currently pursuing development or commercial stage collaborations in the following areas:

  • Biosimilars (including potentially interchangeable biologics)
  • Complex Generics
  • Novel drugs for autoimmune diseases or other specialty areas

If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at businessdevelopment@momentapharma.com.

 

LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.  Glatopa® is a trademark of Novartis AG.

Last Updated 1/4/2017